Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe [Yahoo! Finance]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: Yahoo! Finance
The company currently has one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). The FDA initially approved Caplyta for the treatment of schizophrenia in adults in December 2019, while the commercial launch began in March 2020. In December 2021, Caplyta's indication was further expanded to treat bipolar depression in adults. Caplyta is currently the only approved treatment, both as monotherapy and as adjunctive therapy with lithium or valproate, for depressive episodes associated with bipolar I or II disorder in adults. Moreover, in April 2022, the FDA approved two new dosage strengths of Caplyta, 10.5 mg and 21 mg for patients concomitantly taking strong or moderate CYP3A4 inhibitors and 21 mg for patients with moderate or severe hepatic impairment. These new dosage strengths have expanded the eligible patient population for Caplyta. After the launch of its bipolar depression indication, Caplyta sales have increased, with the drug witnessing robust initial prescripti
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology CongressGlobeNewswire
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $130.00 price target on the stock.MarketBeat
- Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone [Yahoo! Finance]Yahoo! Finance
- Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $92.00 price target on the stock, up previously from $68.00.MarketBeat
ITCI
Earnings
- 8/7/24 - Beat
ITCI
Sec Filings
- 9/6/24 - Form 144
- 8/30/24 - Form 4
- 8/30/24 - Form 144
- ITCI's page on the SEC website